Fennec Pharmaceuticals: Great Sales Progress - Not Yet Reflected In Stock Price [Seeking Alpha]
Fennec Pharmaceuticals Inc. (FENC)
Last fennec pharmaceuticals inc. earnings: 11/12 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.fennecpharma.com/investor-relations
Company Research
Source: Seeking Alpha
A pending EU launch of PEDMARK® provides a near term opportunity for the Company to finalize an EU partnership. Revenue growth in the US, and completion of a Japanese bridging study provide opportunities for further geographic partnerships, or a sale of the Company. Fennec Pharmaceuticals – Revenue Guidance and EU Launch Fennec Pharmaceuticals ( NASDAQ: FENC ) (the Company), is a small cap, commercial-stage biotech company with a single drug, PEDMARK®. PEDMARK is a unique formulation of sodium thiosulfate specifically developed for pediatric patients. PEDMARK is FDA-approved to reduce the risk of ototoxicity or hearing loss associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors. The drug is used in children who receive platinum-based chemotherapy. PEDMARK was launched in the fall of 2022. The Company recently released its sales guidance for Q4 2023 and 2023, a range between $9.2-$9.7M and $20.7-$21.2M, respectively
Show less
Read more
Impact Snapshot
Event Time:
FENC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FENC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FENC alerts
High impacting Fennec Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
FENC
News
- Those who invested in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago are up 136% [Yahoo! Finance]Yahoo! Finance
- Fennec Pharmaceuticals Inc (NASDAQ: FENC) had its price target raised by analysts at HC Wainwright from $17.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
FENC
Earnings
- 3/21/24 - Miss
FENC
Sec Filings
- 5/1/24 - Form 144
- 4/26/24 - Form 4/A
- 4/26/24 - Form 4/A
- FENC's page on the SEC website